369 related articles for article (PubMed ID: 29040228)
1. Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.
Simsek M; Meijer B; Mulder CJJ; van Bodegraven AA; de Boer NKH
Ther Drug Monit; 2017 Dec; 39(6):584-588. PubMed ID: 29040228
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease.
Sánchez Rodríguez E; Ríos León R; Mesonero Gismero F; Albillos A; Lopez-Sanroman A
Gastroenterol Hepatol; 2018 Dec; 41(10):629-635. PubMed ID: 30107940
[TBL] [Abstract][Full Text] [Related]
3. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
Beswick L; Friedman AB; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
[TBL] [Abstract][Full Text] [Related]
5. Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?
Derijks LJ; Hommes DW
Curr Gastroenterol Rep; 2006 Apr; 8(2):89-92. PubMed ID: 16533469
[No Abstract] [Full Text] [Related]
6. A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease.
Cangemi G; Barabino A; Barco S; Parodi A; Arrigo S; Melioli G
Int J Immunopathol Pharmacol; 2012; 25(2):435-44. PubMed ID: 22697075
[TBL] [Abstract][Full Text] [Related]
7. Multicentric Case-Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease.
Stocco G; Martelossi S; Arrigo S; Barabino A; Aloi M; Martinelli M; Miele E; Knafelz D; Romano C; Naviglio S; Favretto D; Cuzzoni E; Franca R; Decorti G; Ventura A
Inflamm Bowel Dis; 2017 Apr; 23(4):628-634. PubMed ID: 28296824
[TBL] [Abstract][Full Text] [Related]
8. Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?
Heerasing NM; Ng JF; Dowling D
Intern Med J; 2016 Apr; 46(4):465-9. PubMed ID: 26425841
[TBL] [Abstract][Full Text] [Related]
9. Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease.
Vikingsson S; Andersson D; Almer S; Peterson C; Hindorf U
J Crohns Colitis; 2014 Dec; 8(12):1702-9. PubMed ID: 25239576
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
[TBL] [Abstract][Full Text] [Related]
12. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides.
Duley JA; Florin TH
Ther Drug Monit; 2005 Oct; 27(5):647-54. PubMed ID: 16175140
[TBL] [Abstract][Full Text] [Related]
13. Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?
Frick S; Müller D; Kullak-Ublick GA; Jetter A
Eur J Clin Pharmacol; 2019 Mar; 75(3):335-342. PubMed ID: 30610277
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
Jharap B; Seinen ML; de Boer NK; van Ginkel JR; Linskens RK; Kneppelhout JC; Mulder CJ; van Bodegraven AA
Inflamm Bowel Dis; 2010 Sep; 16(9):1541-9. PubMed ID: 20155846
[TBL] [Abstract][Full Text] [Related]
15. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study.
Meijer B; Wilhelm AJ; Mulder CJJ; Bouma G; van Bodegraven AA; de Boer NKH
Ther Drug Monit; 2017 Aug; 39(4):399-405. PubMed ID: 28489727
[TBL] [Abstract][Full Text] [Related]
17. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine metabolite testing in inflammatory bowel disease.
Goldberg R; Moore G; Cunningham G; Schulberg J; Marsh P; Brown S; Connell W; Lust M; Kamm MA; Bell S
J Gastroenterol Hepatol; 2016 Mar; 31(3):553-60. PubMed ID: 26510636
[TBL] [Abstract][Full Text] [Related]
19. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD.
Kopylov U; Battat R; Benmassaoud A; Paradis-Surprenant L; Seidman EG
Dig Dis Sci; 2015 Feb; 60(2):478-84. PubMed ID: 25236422
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
Wusk B; Kullak-Ublick GA; Rammert C; von Eckardstein A; Fried M; Rentsch KM
Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1407-13. PubMed ID: 15618853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
